Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes

F. Ong(Netherlands Comprehensive Cancer Organisation), Hanneke C. Kluin‐Nelemans(University Medical Center Groningen), Gabriele Jaques(Netherlands Comprehensive Cancer Organisation), P.J. Seelen(Netherlands Comprehensive Cancer Organisation), P. W. Wijermans(Haga Hospital), Wim de Kieviet(Netherlands Comprehensive Cancer Organisation), J. Hermans(Ludwig-Maximilians-Universität München), Ulrich Kaiser(University of Applied Sciences Landshut)
Blood
January 15, 1996
10.1182/blood.v87.2.712.bloodjournal872712
Cited by 20

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
|Blood|2007|971
Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.
|Journal of Clinical Oncology|1993|552
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer
|The Lancet|1994|389